Company Profile

SUN PHARMACEUTICAL INDUSTRIES LTD.

NSE : SUNPHARMABSE : 524715ISIN CODE : INE044A01036Industry : Pharmaceuticals & DrugsHouse : Sun Pharma
BSE535.006 (+1.13 % )
PREV CLOSE (Rs.) 529.00
OPEN PRICE (Rs.) 532.65
BID PRICE (QTY) 535.00 (96 )
OFFER PRICE (QTY) 535.25 (190 )
VOLUME 254400
TODAY'S LOW / HIGH (Rs.)526.35 541.00
52 WK LOW / HIGH (Rs.)315.2 540.75
NSE536.30 7.45 (+1.41 % )
PREV CLOSE(Rs.) 528.85
OPEN PRICE (Rs.) 533.90
BID PRICE (QTY) 536.25 (448 )
OFFER PRICE (QTY) 536.30 (726 )
VOLUME 6162098
TODAY'S LOW / HIGH(Rs.) 526.15 541.45
52 WK LOW / HIGH (Rs.)312 541

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.01
Dividend Yield(%) 0.74
TTM EPS (Rs.) 12.42
P/E Ratio 43.23
Book Value (Rs.) 103.90
Face Value (Rs.) 1
MCap (Rs. in Mn) 1288202.95
Price/Earning (TTM) 36.30
Price/Sales (TTM) 10.95
Price/Book (MRQ) 5.17
PAT Margin (%) 23.21
ROCE (%) 12.19
Incorporation Year : 1993

Management Info :

Israel Makov - Chairman Dilip S Shanghvi - Managing Director

Registered Office :

Address : Sun Pharma Advanced Research Centre (S P A R C),Tandalja,,
Vadodara,
Gujarat-390020

Phone : 0265- 5515500 / 5515600 / 5515700

Website : www.sunpharma.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
05Aug08-05-2020$Sun Pharma rises on launching FluGuard in India at Rs 35 per tablet Sun Pharma rises on launchin

Sun Pharmaceutical Industries is currently trading at Rs. 532.50, up by 4.00 points or 0.76% from its previous closing of Rs. 528.50 on the BSE.

The scrip opened at Rs. 536.35 and has touched a high and low of Rs. 537.70 and Rs. 530.30 respectively. So far 195543 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 540.75 on 31-Jul-2020 and a 52 week low of Rs. 315.20 on 23-Mar-2020.

Last one week high and low of the scrip stood at Rs. 540.75 and Rs. 487.65 respectively. The current market cap of the company is Rs. 128004.52 crore.

The promoters holding in the company stood at 54.69%, while Institutions and Non-Institutions held 32.81% and 12.50% respectively.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharmaceutical Industries is currently trading at Rs. 532.5..
05Aug08-05-2020$TCS, Sun Pharmaceutical and NMDC to see some action today TCS, Sun Pharmaceutical and

Digitate, a software venture of Tata Consultancy Services (TCS) has launched ignio AI.Assurance, an autonomous assurance product that enables enterprises to deliver better software faster, enhancing their business performance. The new product enables development teams within enterprises to harness the power of artificial intelligence (AI) and machine learning to overcome the bottlenecks and deficiencies of their manual or assisted testing methods, and adopt cutting-edge quality engineering practices for timely software releases that help enterprises deliver unique and compelling customer experiences and enhance their competitive differentiation.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

NMDC has recorded a sharp rise in overall production and sales in July 2020 as compared to the corresponding period in July 2019. During this period, despite the current uncertain situation due to COVID-19, the company has been able to achieve excellent physical performance through its continual push towards higher volumes which saw production of 2.19 million tones (MT) and sales 2.57 MT that grew by 13% and 7% over the corresponding period last year, respectively.

Power Finance Corporation (PFC) is targeting higher fund flow from 54EC capital gain bonds in the last two quarters of this fiscal and expects to register 25 percent growth in funds garnered from this instrument in 2020-21. The company had raised around Rs 1,100 crore from these bonds in 2019-20. However, despite getting good response in the last few years, the firm could not increase funding from this route in the first quarter of this fiscal mainly due to the COVID-19 impact.

Paushak has received approval to its application for amendment in Industrial License from the Department for Promotion of Industrial & Internal Trade, Ministry of Commerce & Industry vide its communication dated August 3, 2020 for expansion of licensed manufacturing capacity at its existing manufacturing facilities located at Panelav, Gujarat. With this approval, the company has announced expansion of licensed manufacturing capacity for the product Phosgene from 4,800 MT per annum to 14,400 MT per annum and graded capacity for its other phosgene based derivatives.

Indian Hotels Company (IHCL) has launched I-ZEST (Zero-Touch Service Transformation), a suite of digital solutions across its hotels under its brands -- Taj, Vivanta and SeleQtions. I-ZEST's digital features will further ensure social distancing for both guests and associates, while maintaining secure and seamless services. The digital initiatives come on the back of the company's foray into food delivery service from its iconic restaurants via a dedicated mobile app.

Lupin has received tentative approval for its Empagliflozin Tablets, 10 mg and 25 mg, from the United States Food and Drug Administration (USFDA) to market a generic version of Jardiance Tablets, 10 mg and 25 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.

Digitate, a software venture of Tata Consultancy Services (TCS)..
04Aug08-04-2020$Sun Pharma launches FluGuard in India at Rs 35 per tablet Sun Pharma launches FluGuard
Sun Pharmaceutical Industries has launched FluGuard (Favipiravir 200 mg) at an economical price of Rs. 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India. Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease.

The company will work closely with the government and medical community to ensure availability of FluGuard to patients across the country. The stocks of FluGuard will be available in the market from this week.

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharmaceutical Industries has launched FluGuard (Favipiravi..
03Aug08-03-2020$Sun Pharmaceutical Industries informs about newspaper advertisement Sun Pharmaceutical Industrie

Sun Pharmaceutical Industries has informed that it has enclosed Newspaper advertisement published regarding notice of the 28th Annual General Meeting of the Company for the financial year 2019-20, to be held on Thursday, August 27, 2020 by Video Conferencing/ Other Audio Visual means, E-voting and Book Closure, under Regulation 30 read with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Sun Pharmaceutical Industries has informed that it has enclosed..
31Jul07-31-2020$Amalgamation Amalgamation
the Scheme of Amalgamation and Merger of Sun Pharma Global FZE (?Transferor Company?), an indirect wholly owned subsidiary of the Company with Sun Pharmaceutical Industries Limited ("Transferee Company" or ?Company?) and their respective members and creditors (?Scheme?) pursuant to Section 234 read with Sections 230 to 232 of the Companies Act, 2013 and the relevant rules and regulations made thereunder for amalgamation of Transferor Company into the Company subject to receipt of necessary approvals of the Hon'ble National Company Law Tribunal at Ahmedabad and all other requisite parties/authorities as may be required to give effect to the Scheme.
the Scheme of Amalgamation and Merger of Sun Pharma Global FZE..
Financials More
Rs. in Millions
QTR Jun 20 ANNUAL 20
Net Profit5319.532111.4
Gross Profit 5315.2 32530
Operating Profit 7432.142225.7
Net Sales 29630.4125319.3
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Aarti Drugs (BSE)
 2046.20 (8.70%)
M.Cap ( in Cr)
4745.86
Valiant Organics (BSE)
 2300.00 (6.24%)
M.Cap ( in Cr)
2782.17
Torrent Pharma (BSE)
 2931.80 (2.49%)
M.Cap ( in Cr)
49709.29
Divis Lab (BSE)
 2727.65 (2.30%)
M.Cap ( in Cr)
72261.87
Caplin Point Lab (BSE)
 604.55 (5.44%)
M.Cap ( in Cr)
4567.31
Shareholding Pattern More
FI/BANKS/INSURANCE 9.38 %
PROMOTERS 54.69 %
NON-INSTITUTION 12.5 %
MUTUAL FUNDS/UTI 10.52 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes